JP2021505137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505137A5 JP2021505137A5 JP2020530356A JP2020530356A JP2021505137A5 JP 2021505137 A5 JP2021505137 A5 JP 2021505137A5 JP 2020530356 A JP2020530356 A JP 2020530356A JP 2020530356 A JP2020530356 A JP 2020530356A JP 2021505137 A5 JP2021505137 A5 JP 2021505137A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- amino acid
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0166969 | 2017-12-06 | ||
| KR20170166969 | 2017-12-06 | ||
| PCT/KR2018/015445 WO2019112347A2 (ko) | 2017-12-06 | 2018-12-06 | 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505137A JP2021505137A (ja) | 2021-02-18 |
| JP2021505137A5 true JP2021505137A5 (https=) | 2021-12-02 |
| JP7089806B2 JP7089806B2 (ja) | 2022-06-23 |
Family
ID=66749962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530356A Active JP7089806B2 (ja) | 2017-12-06 | 2018-12-06 | 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11534462B2 (https=) |
| EP (1) | EP3722313A4 (https=) |
| JP (1) | JP7089806B2 (https=) |
| KR (1) | KR102136063B1 (https=) |
| CN (1) | CN111465616B (https=) |
| AU (1) | AU2018379502B2 (https=) |
| CA (1) | CA3083936C (https=) |
| WO (1) | WO2019112347A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210079111A1 (en) * | 2018-08-04 | 2021-03-18 | AbCyte Therapeutics Inc. | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| CN112759651B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种包含嵌合抗原受体修饰的t细胞及其应用 |
| CN111909277A (zh) * | 2020-08-13 | 2020-11-10 | 上海市第一人民医院 | 一种靶向trbc1的人源化嵌合抗原受体、t细胞及用途 |
| KR102393776B1 (ko) * | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| WO2022234158A1 (es) * | 2021-05-06 | 2022-11-10 | Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) | Terapia de células t con receptor de antígeno quimérico específico de cd19 |
| US20230399375A1 (en) | 2022-04-15 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| CN118359729A (zh) * | 2023-01-19 | 2024-07-19 | 武汉昭智生物技术有限公司 | 一种car分子、包含其的细胞或外泌体及它们的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US7169894B2 (en) * | 2001-11-14 | 2007-01-30 | Mirari Biosciences, Inc. | Methods and compositions for reverse translation |
| HUE025945T2 (en) | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| JP2008546647A (ja) | 2005-06-08 | 2008-12-25 | デューク ユニバーシティ | 移植のための抗−ｃｄ１９抗体治療 |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| CN102421800A (zh) * | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| CN102413839A (zh) | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| US9074002B2 (en) | 2009-04-27 | 2015-07-07 | Cold Spring Harbor Laboratory | PTP1B inhibitors |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| FI2997141T3 (fi) * | 2013-05-13 | 2022-12-15 | CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä | |
| CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| GB2527285B (en) | 2014-06-11 | 2021-05-26 | Advanced Risc Mach Ltd | Resource access control using a validation token |
| TWI751102B (zh) * | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| CN106554414B (zh) * | 2015-09-18 | 2019-04-23 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| MY196631A (en) | 2015-10-13 | 2023-04-24 | Eureka Therapeutics Inc | Antibody Agents Specific for Human Cd19 and uses Thereof |
-
2018
- 2018-12-06 KR KR1020180156433A patent/KR102136063B1/ko active Active
- 2018-12-06 EP EP18886531.5A patent/EP3722313A4/en active Pending
- 2018-12-06 US US16/768,412 patent/US11534462B2/en active Active
- 2018-12-06 CA CA3083936A patent/CA3083936C/en active Active
- 2018-12-06 AU AU2018379502A patent/AU2018379502B2/en active Active
- 2018-12-06 WO PCT/KR2018/015445 patent/WO2019112347A2/ko not_active Ceased
- 2018-12-06 CN CN201880079137.7A patent/CN111465616B/zh active Active
- 2018-12-06 JP JP2020530356A patent/JP7089806B2/ja active Active
-
2022
- 2022-12-06 US US18/075,648 patent/US12090171B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505137A5 (https=) | ||
| JP7404335B2 (ja) | Ｂｃｍａ特異性を有するキメラ抗原受容体およびその使用 | |
| CN109485734B (zh) | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 | |
| JP7721500B2 (ja) | Ｍａｇｅ－ａ４特異性を有するキメラ抗原受容体およびそれらの使用 | |
| CA3032581A1 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| KR20180054590A (ko) | 항글리피칸-3 항체 및 이의 응용 | |
| JP2022542559A5 (https=) | ||
| JP2018526028A5 (https=) | ||
| US20240123068A1 (en) | Cd19 binders, car-t constructs comprising the same, and methods of using the same | |
| WO2018071913A2 (en) | Modular tetrameric bispecific antibody platform | |
| CN111848809A (zh) | 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途 | |
| JP2023539591A5 (https=) | ||
| JP2024516308A5 (https=) | ||
| TW202246504A (zh) | 靶向嵌合抗原受體之ｒｏｒ１ | |
| KR20230022422A (ko) | 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체 | |
| KR20240013173A (ko) | Nkg2d-기초 키메라 항원 수용체 | |
| US20240226154A9 (en) | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same | |
| JP7080514B2 (ja) | 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 | |
| TW202309294A (zh) | 病毒載體生產系統 | |
| JP2021529539A5 (https=) | ||
| KR20240052776A (ko) | Mog-결합 단백질 및 이의 용도 | |
| AU2023230479A1 (en) | Antibody or antigen-binding fragment thereof that targets cotinine, chimeric antigen receptor comprising same, and uses thereof | |
| TW202435913A (zh) | 針對血癌之抗體 | |
| EP4514835A1 (en) | Modified cytotoxic t cells and methods of use thereof | |
| HK40072388A (zh) | TGF-β受体和使用方法 |